Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Verstovsek on the Role of Prognostication in Myelofibrosis

April 7th 2021

Srdan Verstovsek, MD, PhD, discusses the role of prognostication in myelofibrosis.

A Review of Pacritinib and PACIFICA Data

April 7th 2021

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

The Role of Transplant in Myelofibrosis

April 7th 2021

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis.

Abu-Zeinah Outlines Why Interferon-Alpha Should Be Offered to Both Low- and High-Risk Polycythemia Vera

April 5th 2021

Ghaith Abu-Zeinah, MD, shares what inspired the study examining IFN vs standard strategies, key findings from the research, and the clinical implications of these data on the PV treatment paradigm.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Navitoclax Shows Early Signs of Clinical Benefit in Myelofibrosis

April 1st 2021

The combination of navitoclax and ruxolitinib simultaneously inhibits 2 key mechanisms that promote myelofibrosis, resulting in an improvement in symptom control and positive changes in response biomarkers in patients with high-risk disease.

Rolling Submission Completed for Pacritinib for Myelofibrosis With Severe Thrombocytopenia

March 31st 2021

The rolling submission of a new drug application has been completed and submitted to the FDA to support the approval of pacritinib as a treatment for patients with myelofibrosis and severe thrombocytopenia defined as having platelet counts less than 50 x 109/L.

COMFORT Data and Ruxolitinib in Myelofibrosis

March 31st 2021

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

A Look at Fedratinib and the JAKARTA Trials

March 31st 2021

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice.

Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia Vera

March 30th 2021

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis

March 24th 2021

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Goals in Treating Low-Risk Primary Myelofibrosis

March 24th 2021

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic.

Emerging Therapeutic Options in Polycythemia Vera

March 17th 2021

What to look forward to in the polycythemia vera space, including new clinical trials.

Real-World Use of Ruxolitinib in Polycythemia Vera

March 17th 2021

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera.

FDA Issues Complete Response Letter for Ropeginterferon Alfa-2b for Polycythemia Vera

March 15th 2021

The FDA has issued a complete response letter regarding the biologics license application for ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera.

Polycythemia Vera: An Update on Clinical Trials

March 10th 2021

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.

PV Progression and Guideline-Directed Management

March 10th 2021

Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.

Interferon-Alpha Improves MFS and OS Over Standard Approaches in Polycythemia Vera

March 9th 2021

Interferon-alpha has been shown to significantly improve both myelofibrosis-free survival and overall survival over hydroxyurea and phlebotomy only in patients with polycythemia vera.

Approaches Abound for Managing Symptoms Associated With Myelofibrosis

March 4th 2021

Srdan Verstovsek, MD, PhD, shares recommendation updates for myelofibrosis treatment and emerging options under exploration to effectively manage disease-related symptoms.

Targeted DNA Sequencing Informs Posttransplant Relapse Rates in MDS

March 3rd 2021

Targeted DNA sequencing prior to transplant can be used to determine which patients with myelodysplastic syndrome are at high risk for posttransplant relapse and should forego reduced-intensity conditioning in lieu of myeloablative conditioning.